Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
81 hedge funds and large institutions have $126M invested in Navidea Biopharmaceuticals Inc. in 2015 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 10 closing their positions.
50% more capital invested
Capital invested by funds: $84.6M → $126M (+$41.9M)
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
3% more funds holding
Funds holding: 79 → 81 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
98% less call options, than puts
Call options by funds: $332K | Put options by funds: $14M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
+$1.53M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.35M |
| 3 |
Jane Street
New York
|
+$1.16M |
| 4 |
PM
Platinum Management
New York
|
+$969K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$872K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$789K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$608K |
| 3 |
Goldman Sachs
New York
|
-$454K |
| 4 |
Bank of New York Mellon
New York
|
-$232K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$90K |
NAVB Hedge Fund Activity: Q3 2015 in Review
81 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2015, worth a combined $126M — up 50% from $84.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new NAVB positions and 10 closed out — a net gain of 2 holders — while 23 added to existing stakes and 20 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $1.53M. The largest seller was TFS Capital, exiting entirely with an estimated $789K sold.
- 81 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2015, up from 79 in Q2 2015.
- Funds reported $126M of Navidea Biopharmaceuticals Inc. stock for Q3 2015, up 50% quarter-over-quarter.
- 12 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2015 and 10 closed out, a net change of +2 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2015 was EAM Investors, an estimated $1.53M added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q3 2015 was TFS Capital, an estimated $789K sold.
Based on aggregated 13F filings for Q3 2015.